Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carotuximab - Santen Pharmaceutical/TRACON Pharmaceuticals

Drug Profile

Carotuximab - Santen Pharmaceutical/TRACON Pharmaceuticals

Alternative Names: Chimeric Antibody TRC105; DE-122; NSC#754227; TRC-105

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roswell Park Cancer Institute
  • Developer National Cancer Institute (USA); Santen Pharmaceutical; TRACON Pharmaceuticals; University of Alabama at Birmingham; University of Minnesota
  • Class Antifibrotics; Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Choriocarcinoma; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Haemangiosarcoma; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Wet age-related macular degeneration

Most Recent Events

  • 09 Mar 2020 Discontinued - Phase-I/II for Wet age-related macular degeneration in USA (Intravitreous)
  • 09 Mar 2020 Discontinued - Phase-II for Wet age-related macular degeneration (Combination therapy) in USA and Philippines (Intravitreous)
  • 27 Sep 2019 Efficacy and adverse event data from the phase II TRAXAR trial in Renal cell carcinoma presented at the 44th European Society for Medical Oncology Congress (ESMO-2019)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top